Controversy remains over ‘pay for delay’
Published: 2011-09-27 06:58:00
Updated: 2011-09-27 06:58:00
A tactic used in some drug patent settlement cases is creating renewed controversy concerning so-called “pay for delay” agreed between GlaxoSmithKline and Dong-A, which was made public by the Fair Trade Commission Thursday.
However, GSK said Thursday that it did not make any agreements with Do...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
